Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221310 · ClinicalTrials.gov registry record · Phase 2
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
A Phase 2 study of Myelodysplastic Syndrome and Acute Myelogenous Leukemia, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02221310 is a Phase 2 study of Myelodysplastic Syndrome and Acute Myelogenous Leukemia that has completed, run by New York Medical College. The registered enrollment target is 25 participants, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02221310, a Phase 2 study of Myelodysplastic Syndrome and Acute Myelogenous Leukemia, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
Conditions Studied
Interventions
- DRUG Gemtuzumab Ozogamicin
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-12-07 |
| Est. Completion | 2023-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02221310
The ClinicalTrials.gov registry entry for NCT02221310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (88% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Gemtuzumab Ozogamicin is the first listed.
NCT02221310 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02221310 about?
NCT02221310 is a clinical study titled "Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS". Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
What is the current status of trial NCT02221310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-12-07. Estimated completion is 2023-04-04.
What conditions does trial NCT02221310 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT02221310?
The interventions under investigation include: Gemtuzumab Ozogamicin (DRUG).
Who is sponsoring clinical trial NCT02221310?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02221310 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.